People: Impax Laboratories, Inc. (IPXL.O)

IPXL.O on Consolidated Issue listed on NASDAQ Global Market

13.66USD
9 Feb 2010
Price Change (% chg)

$0.02 (+0.15%)
Prev Close
$13.66
Open
--
Day's High
$13.93
Day's Low
$13.50
Volume
358,109
Avg. Vol
581,914
52-wk High
$14.87
52-wk Low
$3.00

view people for:

Summary

Name Age Since Current Position
Burr, Robert 58 Chairman of the Board
Hsu, Larry 60 2006 President, Chief Executive Officer, Director
Koch, Arthur 55 2005 Chief Financial Officer, Senior Vice President - Finance
Nestor, Michael 56 2008 President - Impax Pharmaceutical Division
Mengler, Christopher 46 2009 President, Global Pharmaceuticals Division
Hildenbrand, Charles 57 2004 Senior Vice President - Operations
Markbreiter, Michael 47 1997 Director
Oh, Kim Sun 61 1999 Director
Fleming, Nigel 54 1999 Director
Benet, Leslie 71 2001 Director
Terreri, Peter 51 2003 Director
» Insider Trading

Biographies

Name Description
Burr, Robert Robert L. Burr has served as Chairman and Director of Impax Laboratories, Inc. He is also the Director of the Company since 2001. Mr. Burr is a partner of Fleming US Discovery Partners, L.P., a private equity sponsor affiliated with J.P. Morgan Chase & Co. Mr. Burr was employed by J.P. Morgan Chase & Co. and associated entities from 1995 to May 2008, at which time he resigned his position as Managing Partner of the Fleming US Discovery III Funds. From 1992 to 1995, Mr. Burr was head of Private Equity at the investment banking firm of Kidder, Peabody & Co., Inc. Prior to that time, Mr. Burr served as the Managing General Partner of Morgan Stanley Ventures and General Partner of Morgan Stanley Venture Capital Fund I, L.P. and was a corporate lending officer with Citibank, N.A. Mr. Burr received an MBA from Columbia University and a BA from Stanford University.
Hsu, Larry Larry Hsu, Ph.D. has been President, Chief Executive Officer and Director of Impax Laboratories, Inc. since October 1, 2006. Prior to holding these positions, Dr. Hsu served as President and Chief Operating Officer beginning in 1999. Dr. Hsu co-founded Impax Pharmaceuticals, Inc. in 1994 and served as its President, Chief Operating Officer and a member of the board from its inception until its merger with Impax Laboratories, Inc. From 1980 to 1995, Dr. Hsu worked at Abbott Laboratories, where, during his last four years, he served as Director of Product Development in charge of formulation development, process engineering, clinical lot manufacturing and production technical support of all dosage forms, managing a staff of approximately 250 people. Dr. Hsu obtained his Ph.D. in pharmaceutics from the University of Michigan.
Koch, Arthur Mr. Arthur A. Koch has served as Chief Financial Officer, Senior Vice President - Finance of Impax Laboratories, Inc. since March 2005. Prior to joining Impax, Mr. Koch was employed by Strategic Diagnostics Inc., a company which develops, manufactures and markets immunoassay-based diagnostic test kits. While at Strategic Diagnostics Inc., Mr. Koch served as Chief Operating Officer for six years, interim Chief Executive Officer for five months and Chief Financial Officer and Vice President for five years. In addition, Mr. Koch has previously held Chief Financial Officer positions at Paracelsian Inc., IBAH Inc., Liberty Fish Company, and Premier Solutions Ltd. Mr. Koch holds a Bachelor of Business Administration from Temple University and has been a Certified Public Accountant since 1977.
Nestor, Michael Mr. Michael J. Nestor joined in March 2008 as the President of newly formed branded products division of Impax Laboratories, Inc., Impax Pharmaceuticals. Before joining the company, he was Chief Operating Officer of Piedmont Pharmaceuticals a specialty pharmaceutical company. Prior to Piedmont, Mr. Nestor was CEO of NanoBio, a startup biopharmaceutical company, prior to which he was employed by Alpharma, initially as President of its generic pharmaceutical business and later as President of its branded pharmaceutical business. Before this he was President, International business at Banner Inc, a global contract manufacturing concern. Mr. Nestor spent 16 years at Lederle Laboratories / Wyeth holding increasing positions of responsibility including Vice President, Cardiovascular business, Vice President / General Manager of Lederle-Praxis Biologics, and Vice President of Wyeth-Lederle Vaccines and Pediatrics. Mr. Nestor has experience in a number of pharmaceutical therapeutic areas including vaccines, anti-infectives, dermatologics, CNS, generics, and analgesics. Mr. Nestor has a Bachelor of Business Administration degree from Middle Tennessee State University and a MBA from Pepperdine University.
Mengler, Christopher Christopher Mengler joined Impax Laboratories Inc in January 2009 as President of generic products division, Global Pharmaceuticals. Before joining he was employed by Barr Laboratories, Inc. (“Barr”). Since 2002, Barr employed Mr. Mengler in the following capacities: (i) Executive Vice President, Global Strategic Planning; (ii) Senior Vice President, Corporate Development; and (iii) Vice President, Strategic Planning. As Executive Vice President, Global Strategic Planning, Mr. Mengler was responsible for the global cross-functional development of Barr’s generic R&D and commercial products portfolio. Prior to joining Barr, Mr. Mengler held various positions, including key management positions, with Pfizer Inc. and Sterling Winthrop Inc. Mr. Mengler earned a B.S. in Mathematical Sciences and Operations Research from Johns Hopkins University, a B.S. in Pharmacy from St. John’s University and his MBA from Bernard M. Baruch College in New York.
Hildenbrand, Charles Mr. Charles V. Hildenbrand is Senior Vice President, Operations, a position he has held since he joined of Impax Laboratories, Inc. in September 2004. From 1996 until September 2004, Mr. Hildenbrand worked for the PF Laboratories, Inc. as Plant Manager until 2001, and then as Executive Director of Engineering and Technical Services. From 1983 until 1996, Mr. Hildenbrand worked at Lederle Laboratories/Wyeth as Section Head of Biochemical Production, Manager of Filing and Packaging, and then Production Director of Consumer Health Products. Mr. Hildenbrand holds a B.S. in Chemical Engineering from Villanova University, as well as an MBA from Lehigh University.
Markbreiter, Michael Michael Markbreiter has been a Director of Impax Laboratories, Inc. since 1997. He has been a portfolio manager for Sofaer Capital, a global hedge fund, since December 2000. From August 1995 to December 1998, Mr. Markbreiter was a portfolio manager for private equity investments for Kingdon Capital Management Corp., a New York hedge fund. In April 1994 he co-founded Ram Investment Corp., a venture capital company. From March 1993 to January 1994, Mr. Markbreiter was an analyst at Alliance Capital Management Corp. From July 1983 to September 1989, Mr. Markbreiter was an Executive Editor for Arts of Asia magazine. Mr. Markbreiter graduated from Cambridge University with a degree in Engineering.
Oh, Kim Sun Oh Kim Sun has served as a Director of Impax Laboratories, Inc. since 1999. Mr. Oh has been employed by the Chemical Company of Malaysia Berhad (CCM), a Malaysian corporation whose stock is listed on the Bursa Malaysia Berhad, since 1983 and served as Executive Director from 1983 through October 2003. Currently, Mr. Oh is a member of the board of directors of Nikko Electronics Berhad, Pharmaniaga Berhad, UEM Land Holdings Berhad and Faber Group Berhad, all of which are listed on the Bursa Malaysia Berhad. Mr. Oh is also a director of various other companies in Kuala Lumpur. Mr. Oh is also a member of The Malaysian Institute of Certified Public Accountants.
Fleming, Nigel Nigel Ten Fleming, Ph.D. has served as Director of Impax Laboratories Inc. since 1999. He is Chairman of Minerva Healthcare, an emerging specialty pharmaceutical company and, in 2008, he became Chairman and Chief Executive Officer of G2B Pharma. He previously founded Athena Diagnostics, a neurological diagnostics reference laboratory, serving variously as Chairman, CEO and Vice President of Business Development prior to the company’s 1995 sale to Athena Neurosciences /Elan Pharmaceuticals. Dr. Fleming has also served on the boards of directors of Examplar, a subsidiary of Transgenic Sciences Inc. that developed the first transgenic Alzheimer’s mouse model, and serves on the board of Genmedica Therapeutics, an oral insulin company based in Barcelona. He has also consulted for, and served in various leadership roles at a number of early-stage biotechnology companies, including Gamera Biosciences, Neurocal, Nephros’, TheraMed Partners and Plant Cell Technologies. Dr. Fleming obtained his Ph.D. in Clinical Biochemistry from the University of Cambridge in England and was a lecturer at Harvard Medical School for a number of years.
Benet, Leslie Leslie Z. Benet, Ph.D. has served as Director of Impax Laboratories Inc. since 2001. He has been a Professor since 1969 of, and has also served as Chairman of, the Department of Biopharmaceutical Sciences, University of California, San Francisco. Dr. Benet has since 1995 been Chairman, President or Chief Executive Officer of AvMax Inc., a biopharmaceutical company. He received his A.B. (English), B.S. (Pharmacy), and M.S. from the University of Michigan, and his Ph.D. from the University of California. Dr. Benet has received six honorary doctorates: Uppsala University, Sweden (Pharm.D., 1987); Leiden University, The Netherlands (Ph.D., 1995); University of Illinois at Chicago (D.Sc., 1997); Philadelphia College of Pharmacy and Science (D.Sc., 1997); Long Island University (D.Sc., 1999); and University of Athens (Ph.D., 2005). He is listed among the 250 most highly cited pharmacologists worldwide. In 1985, Dr. Benet served as President of the APhA Academy of Pharmaceutical Sciences. During 1986, Dr. Benet was a founder and first President of the American Association of Pharmaceutical Scientists (AAPS). In 1987, Dr. Benet was elected to membership in the Institute of Medicine (IOM) of the National Academy of Sciences. Dr. Benet has received the highest scientific awards of AAPS (1989 and 2000), Rho Chi (1990), American Association of Colleges of Pharmacy (1991), American Society for Clinical Pharmacology and Therapeutics (1995), American Pharmaceutical Association (2000), International Pharmaceutical Federation (2001) and in 2004 received the Pharmaceutical Sciences World Congress Research Achievement Award and the Controlled Release Society Career Achievement in Oral Drug Delivery Award. Dr. Benet formerly served as Chair of the FDA Expert Panel on Individual Bioequivalence and the FDA Center for Biologics Peer Review Committee, and as a member of the FDA Science Board and the Generic Drugs Advisory Committee. Dr. Benet presently serves as a member of the IOM Forum on Drug Discovery, Development and Translation.
Terreri, Peter Peter R. Terreri has been a Director of Impax Laboratories, Inc. since 2003. He has over 20 years of experience primarily in generic pharmaceuticals with a specialized expertise in finance. Mr. Terreri is President, Chief Executive Officer and director of CGM, Inc., a manufacturing company that he owns and operates. He previously served as Senior Vice President and Chief Financial Officer of Teva Pharmaceuticals USA from 1985 through 2000, where he actively participated in the growth of the company from a $20 million local generic pharmaceutical company into a global leader in generic pharmaceuticals. As an active member of senior management, he was involved in all facets of the decision-making process at Teva Pharmaceuticals USA, including structuring and negotiating company and product acquisitions, participating in multiple public financings and securing several licensing deals and a substantial credit line. In addition to his role as Chief Financial Officer, Mr. Terreri contributed to many areas related to the company’s success outside of finance, including product development selection, facility utilization, business development, strategic planning, and implementing integration plans for the company’s acquisitions. He also supervised areas such as operations, sales and marketing, and information technology during his tenure.

Basic Compensation

Name Fiscal Year Total
Burr, Robert --
Hsu, Larry 1,710,090
Koch, Arthur 919,338
Nestor, Michael 725,972
Mengler, Christopher --
Hildenbrand, Charles 736,309
Markbreiter, Michael --
Oh, Kim Sun --
Fleming, Nigel --
Benet, Leslie --
Terreri, Peter --
As Of 30 Dec 2008

Options Compensation

Name Options Value
Burr, Robert 0 0
Hsu, Larry 558,580 6,637,780
Koch, Arthur 0 0
Nestor, Michael 0 0
Mengler, Christopher 0 0
Hildenbrand, Charles 0 0
Markbreiter, Michael 0 0
Oh, Kim Sun 0 0
Fleming, Nigel 0 0
Benet, Leslie 0 0
Terreri, Peter 0 0

Insider Trading

Name Shares Traded Price
HSU LARRY CHUNG CHIANG 2,235 $0.00
HSU LARRY CHUNG CHIANG 2,235 $0.00
HSU LARRY CHUNG CHIANG 550 $11.34
SUN OH KIM 2,000 $4.00
MARKBREITER MICHAEL 2,000 $4.00
MARKBREITER MICHAEL 4,000 $9.70
MARKBREITER MICHAEL 2,000 $5.63
HSU LARRY CHUNG CHIANG 9,200 $0.00
HSU LARRY CHUNG CHIANG 715 $9.23
HSU LARRY CHUNG CHIANG 1,000 $0.00
HSU LARRY CHUNG CHIANG 9,000 $0.00
HSU LARRY CHUNG CHIANG 6,000 $0.00
FLEMING NIGEL 4,000 $4.00
FLEMING NIGEL 4,000 $7.69
HSU LARRY CHUNG CHIANG 2,249 $0.00
HSU LARRY CHUNG CHIANG 2,249 $0.00
NESTOR MICHAEL 2,681 $7.55
FLEMING NIGEL 12,000 $0.00
HSU LARRY CHUNG CHIANG 138,000 $0.00
MARKBREITER MICHAEL 12,000 $0.00
NESTOR MICHAEL 13,000 $0.00
KOCH ARTHUR A JR 89,000 $0.00
HILDENBRAND CHARLES V 27,000 $0.00
SUN OH KIM 12,000 $0.00
BURR ROBERT L 12,000 $0.00
» Full list on Insider Trading
view people for: